[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condition:ebv-positive-diffuse-large-b-cell-lymphoma-not-otherwise-specified":3},{"name":4,"total":5,"recruiting":5,"trials":6,"biomarkers":34,"states":35},"EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified",4,[7,15,22,28],{"nct_id":8,"title":9,"phases":10,"status":12,"updated_at":13,"content_modified":14},"NCT05934448","Pembro Plus CAR T-cell Therapy in R\u002FR in PMBCL",[11],"Phase 2","RECRUITING","2026-08-26T02:16:29.226604Z","2026-05-05T02:43:27.574296Z",{"nct_id":16,"title":17,"phases":18,"status":12,"updated_at":20,"content_modified":21},"NCT04231877","Polatuzumab Vedotin and Combination Chemotherapy With or Without Glofitamab for the Treatment of Untreated Aggressive Large B-cell Lymphoma",[19],"Phase 1","2026-08-03T01:58:01.892442Z","2026-05-05T02:43:28.077600Z",{"nct_id":23,"title":24,"phases":25,"status":12,"updated_at":26,"content_modified":27},"NCT07097363","Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for the Treatment of Aggressive B-Cell Non-Hodgkin Lymphoma",[11],"2026-08-26T02:19:30.857183Z","2026-05-05T02:43:27.261789Z",{"nct_id":29,"title":30,"phases":31,"status":12,"updated_at":32,"content_modified":33},"NCT06834373","Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before CAR T-cell Therapy",[11],"2026-08-26T02:16:14.341106Z","2026-05-05T02:43:26.687370Z",[],[]]